CN100430380C - 用作放射指示剂和显象剂的吡啶基乙炔类化合物 - Google Patents

用作放射指示剂和显象剂的吡啶基乙炔类化合物 Download PDF

Info

Publication number
CN100430380C
CN100430380C CNB2004800273094A CN200480027309A CN100430380C CN 100430380 C CN100430380 C CN 100430380C CN B2004800273094 A CNB2004800273094 A CN B2004800273094A CN 200480027309 A CN200480027309 A CN 200480027309A CN 100430380 C CN100430380 C CN 100430380C
Authority
CN
China
Prior art keywords
formula
compound
methyl
acid addition
cyclohex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800273094A
Other languages
English (en)
Chinese (zh)
Other versions
CN1856468A (zh
Inventor
F·加斯帕里尼
Y·奥贝松
L·凯斯勒
S·M·阿梅塔梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1856468A publication Critical patent/CN1856468A/zh
Application granted granted Critical
Publication of CN100430380C publication Critical patent/CN100430380C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB2004800273094A 2003-09-26 2004-09-24 用作放射指示剂和显象剂的吡啶基乙炔类化合物 Expired - Fee Related CN100430380C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0322612.3 2003-09-26
GBGB0322612.3A GB0322612D0 (en) 2003-09-26 2003-09-26 Organic compounds

Publications (2)

Publication Number Publication Date
CN1856468A CN1856468A (zh) 2006-11-01
CN100430380C true CN100430380C (zh) 2008-11-05

Family

ID=29286926

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800273094A Expired - Fee Related CN100430380C (zh) 2003-09-26 2004-09-24 用作放射指示剂和显象剂的吡啶基乙炔类化合物

Country Status (13)

Country Link
US (2) US8674110B2 (enExample)
EP (1) EP1670762B1 (enExample)
JP (1) JP4965255B2 (enExample)
CN (1) CN100430380C (enExample)
AU (2) AU2004275971B2 (enExample)
BR (1) BRPI0414732A (enExample)
CA (1) CA2539469C (enExample)
ES (1) ES2400713T3 (enExample)
GB (1) GB0322612D0 (enExample)
MX (1) MXPA06003424A (enExample)
PL (1) PL1670762T3 (enExample)
PT (1) PT1670762E (enExample)
WO (1) WO2005030723A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
CN102753527B (zh) 2010-02-02 2014-12-24 诺华股份有限公司 用作crf受体拮抗剂的环己基酰胺衍生物
CN103097391B (zh) 2010-07-09 2015-04-08 雷科尔达蒂爱尔兰有限公司 作为mGlu5拮抗剂的新型螺环杂环化合物
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
AU2013255458A1 (en) 2012-05-03 2014-10-09 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016121A1 (en) * 1999-08-31 2001-03-08 Merck & Co., Inc. Heterocyclic compounds and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6843979B2 (en) 1999-04-26 2005-01-18 Emory University 4-haloethenylphenyl tropane:serotonin transporter imaging agents
EP1048302A3 (en) 1999-04-30 2002-07-17 Pfizer Products Inc. Radiotracers for in vivo study of acetylcholinesterase and Alzheimer's disease
AU5613900A (en) * 1999-06-30 2001-01-31 Sun Microsystems, Inc. Customizing web content based on network conditions
GB0103045D0 (en) * 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
JP4070431B2 (ja) 2001-07-10 2008-04-02 ジーイー・ヘルスケア・リミテッド モノアミン再取込み部位のマッピング用ヨウ素付加神経プローブ
EP1556142A4 (en) 2002-10-24 2006-11-08 Merck & Co Inc ALKYN DERIVATIVES AS TRACERS FOR THE METABOTROPE GLUTAMATE RECEPTOR BINDING

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016121A1 (en) * 1999-08-31 2001-03-08 Merck & Co., Inc. Heterocyclic compounds and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
[3H] -M-MPEP,a Potent Subtype-Selective .... GASPARINI,F.等.BIOORG. MED. CHEM. LETT.,Vol.12 . 2002 *

Also Published As

Publication number Publication date
MXPA06003424A (es) 2006-06-20
AU2004275971B2 (en) 2008-10-02
US20140142318A1 (en) 2014-05-22
EP1670762A1 (en) 2006-06-21
AU2008261192A1 (en) 2009-01-22
PL1670762T3 (pl) 2013-05-31
CA2539469A1 (en) 2005-04-07
WO2005030723A1 (en) 2005-04-07
CA2539469C (en) 2012-06-19
AU2004275971A1 (en) 2005-04-07
US8674110B2 (en) 2014-03-18
US20090010838A1 (en) 2009-01-08
JP4965255B2 (ja) 2012-07-04
GB0322612D0 (en) 2003-10-29
AU2008261192B2 (en) 2011-08-04
ES2400713T3 (es) 2013-04-11
PT1670762E (pt) 2013-02-07
BRPI0414732A (pt) 2006-11-21
CN1856468A (zh) 2006-11-01
JP2007506698A (ja) 2007-03-22
EP1670762B1 (en) 2012-12-05

Similar Documents

Publication Publication Date Title
US20140142318A1 (en) Pyridylacetylenes for use as radiotracers and imaging agents
JP5246699B2 (ja) フラーレン誘導体の製造方法
TW200812945A (en) Method for making sulfonic acid ester
CN104292155A (zh) 放射性标记的试剂和方法
CN102617434B (zh) 一锅法制备维达列汀
CN105254655B (zh) 一种基于bodipy的荧光氨基酸及其合成方法与应用
CN102249941A (zh) 一种具有抗癌活性的单羟基二正癸基大黄素季铵盐
CN107556155B (zh) 一种合成α,β-双溴化合物的方法
JP2007506698A5 (enExample)
US7803960B2 (en) Phenyloxyaniline derivatives
CN108409602A (zh) 一种制备α-芳基腈化合物的方法
JPS59118784A (ja) 置換イミダゾ〔１，５−ａ〕ピリジン及びその製造方法，並びに該化合物を含有する医薬
CN105753643A (zh) 一种2,5-二溴碘苯的合成方法
CN113583012B (zh) 一种吡喃并[4,3-b]吡啶-2,7-二酮化合物的合成方法
CN104592006B (zh) 一种苯丙酸类化合物的合成方法
CN116514795A (zh) 3CLpro蛋白酶抑制剂的制备方法
CN116730882A (zh) 一类1,6-二炔化合物的结构及其应用
WO2006107106A1 (ja) 小胞アセチルコリントランスポーターに対するリガンド
JP5633873B2 (ja) フラーレン二量体およびその製造方法
CN107118210A (zh) 一种3‑碘‑6‑（三氟甲基）咪唑并[1,2‑a]吡啶的制备工艺
CN110669013A (zh) 一种噁拉戈利中间体的制备方法
CN102584555A (zh) 一锅法制备普拉格雷中间体的方法
CN101041636B (zh) 一种合成杂环烯酮缩胺衍生物的方法
JPS6216462A (ja) ４−シアノピペリジン誘導体
CN117645555A (zh) 一种利用连续流管式反应器合成沙库巴曲中间体的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081105

Termination date: 20140924

EXPY Termination of patent right or utility model